3 Top Biopharma Companies for Second Half of 2018

Todd William | |

Allergan, Pfizer, and Johnson & Johnson are poised to make big moves.

​Schwab and iShares Funds for Dividend Growth

MoneyShow | |

When in doubt, hold a couple of ETFs.

NIH Launches Multi-Organizational Partnership to Advance Parkinson's Disease Clinical Trials

Edward Kim | |

To identify and validate promising biomarkers for Parkinson's disease (Image: NIH)

​Why J&J, Pfizer and Amgen Are Strong Pharma Picks

MoneyShow | |

Big Pharma has deep pockets, growth through new drugs and price increases and strong balance sheets.

​The Pharma Stocks We’re Buying Now

Vitaliy Katsenelson | |

Drumroll, please...

Lilly Gets FDA Approval for Advanced Breast Cancer Treatment

Edward Kim | |

New targeted treatment option for certain patients with breast cancer who are not responding to existing therapies (Image: National Cancer Institute).

SpringWorks Therapeutics Spins Out of Pfizer with $103 Million Series A

Edward Kim | |

The new spin off will start life with 4 clinical stage candidates.

​Here's The Real Importance Of The Latest Novartis AG (ADR) (NYSE:NVS) News

Mark Collins | |

Here's what just happened with Novartis and why it's so important.

​Allergan: Botox and Beyond in Biotech

MoneyShow | |

What's the drug giant been up to?

Tax Reform Uncertainty Dampening Biotech M&A

Edward Kim | |

Lowest level of biotech M&A activity in 4 years.

Sponsored Financial Content

Market Movers